CAPT-ACTP 2025

“From Challenge to Change: Driving Progress in Canada’s Healthcare Landscape”

September 22-23, 2025

MaRS Discovery District

101 College St, Toronto, ON M5G 0A3

Keynote Address: Transforming Health: Life Cycle Assessment for Learning Healthcare – Dr. Dean Regier, Senior Scientist at BC Cancer Research Institute >> (Slides not provided)
Modernizing Market Access: Evolving Pharmacoeconomic Methodologies in Canadian HTA >> Download Slides
Accelerating Patient Access: Addressing Gaps in Implementation Readiness >> Download Slides
Caring for an Aging Population: Policy and Advocacy for Brain Health >> Dowload Slides
Maximizing the Value of PSP Data for Decision Making >> Download Slides
The Evolution of the ‘Big C’: From Cancer to Cure >> Download Slides

Abstract # 24: Measuring the impact of the substitution of innovator biologics with biosimilars on uptake and costs among Ontario Drug Benefit recipients (Presented by Martin Ho) >> (Slides not provided)
Abstract # 49: No Cause for Concern: Early eGFR Decline Following SGLT2 Inhibitor Use in People with HIV Mirrors Trends of the General Population >> (Presented by Lara Haidar) >> (Slides not provided)
Abstract # 68: Relative-age effect on ADHD diagnosis and pharmacologic treatment in children (Presented by Andrew Li) >> Download Slides
Abstract # 3: Fluoroquinolones and the associated risk of panic attacks: A systematic review and active-comparator restricted disproportionality analysis (Presented by Bala Swetha Baskaran) >> Download Slides

Patient Impact in CDA-AMC Reimbursement Reviews: How Can We Build on Progress to Date? >> Download Slides
Early Detection and Better Access: Advancing the Continuum of Breast Cancer Care in Canada >> Download Slides
Building Canada’s Rare Disease Strategy: Strengthening Canada with a Truly National Approach to Rare Diseases >> Download Slides
AGM Meeting:
- Meeting Minutes Link
- Meeting Slides Link

Best Oral Presentation – Martin Ho
- “Measuring the impact of the substitution of innovator biologics with biosimilars on uptake and costs among Ontario Drug Benefit recipients”
Best Poster Presentation – Atafeh Jafari
- “Representativeness of Vulnerable Populations in Randomized Controlled Trials Evaluating the Efficacy and Safety of SGLT-2 Inhibitors: A Systematic Review and Meta-analysis”
Peggy Kee Award – Soo Jin Seung
- “Evaluating Healthcare Resource Utilization and Costs of Individuals Diagnosed with Cancer Exposed versus Unexposed to the Edmonton Symptom Assessment System (ESAS)”
Kris Schindel Award – Mina Tadrous

AstraZeneca • RAREi • Eisai • Cencora – Innomar • Merck • IQVIA • Johnson&Johnson • Novartis

Roche • Pfizer

CSL Behring • McKesson Canada • AbbVie • Amgen • Pivina • Astellas

J.L. Glennie Consulting • Eversana • MORSE Consulting

CDA-AMC • Département de médecine sociale et préventive, Université Laval • HOPE Research Centre